OCU-400 Market Summary

Key Factors Driving OCU-400 Growth

1. First-in-class modifier gene therapy (broad, gene-agnostic approach)

• OCU400 uses the NR2E3 nuclear hormone receptor gene to “reset” retinal gene networks and restore homeostasis.
• Unlike traditional gene therapies targeting a single mutation, OCU400 is mutation-agnostic, addressing multiple RP genotypes.

2. Strong clinical efficacy and durability (key validation driver)

• Phase I/II data showed:

o 100% (9/9) patients demonstrated improvement or stabilization in visual function

o Statistically significant improvement in low-luminance visual acuity (p=0.01)

• Additional data:

o ~83% patients showed stabilization or improvement across visual endpoints

o Durable benefit maintained up to 2–3 years

3. Large unmet need in retinitis pigmentosa

• RP affects:

o ~2 million patients globally (~300,000 in US/EU)

• Most patients lack effective treatment options

4. Late-stage development with clear regulatory pathway

• Phase III (liMeliGhT) enrollment completed (largest gene therapy trial in broad RP)
• Topline data expected: Q1 2027
• BLA submission planned: ~2026–2027

5. One-time treatment model (high economic value)

• Designed as a single administration gene therapy

Growth implication:

• High upfront pricing similar to other retinal gene therapies
• Strong lifetime value per patient, despite one-time dosing

6. Strategic partnerships and commercialization readiness

• Regional licensing deal (e.g., Korea):

o Up to $11M upfront/milestones + 25% royalties

o Sales milestones tied to commercialization performance

• Company building global partnership strategy pre-launch

OCU-400 Recent Developments

• In March 2026, Ocugen completed enrollment in liMeliGhT, its Phase III clinical trial of OCU400 for the treatment of retinitis pigmentosa (RP). The company describes liMeliGhT as a 1-year clinical trial that will support the Biologics License Application (BLA) filing for OCU400 and potential approval in 2027.
• In January 2025, Ocugen, a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, announced a positive 2-year safety and efficacy update for the Phase I/II OCU400 clinical trial. OCU400 is intended for the treatment of early to advanced retinitis pigmentosa (RP) in pediatric and adult populations. Currently, about 2 million patients globally (~300,000 in US/EU) desperately need rescue, otherwise they can potentially become legally blind at some point in their life. OCU400 is intended to treat all these patients with a one-time therapy.

“OCU-400 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of OCU-400 for potential indication like Retinitis pigmentosa and Leber congenital amaurosis in the 7MM. A detailed picture of OCU-400’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the OCU-400 for potential indications. The OCU-400 market report provides insights about OCU-400’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current OCU-400 performance, future market assessments inclusive of the OCU-400 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of OCU-400 sales forecasts, along with factors driving its market.

OCU-400 Drug Summary

OCU-400 is an investigational, adeno-associated virus (AAV)-based gene therapy developed by Ocugen for the treatment of inherited retinal diseases, including retinitis pigmentosa and Leber congenital amaurosis. Unlike traditional gene replacement therapies that target single gene mutations, OCU-400 utilizes a modifier gene approach by delivering the NR2E3 gene, which regulates multiple retinal functions and photoreceptor survival pathways. Administered via a one-time subretinal injection, the therapy aims to restore retinal homeostasis, improve photoreceptor function, and slow or halt disease progression across a broad range of genetic mutations. Preclinical and early clinical data have demonstrated potential improvements in visual function and retinal structure, supporting its development as a mutation-agnostic therapy. OCU-400 is currently in Phase I/II clinical trials, positioning it as a promising next-generation gene therapy candidate for patients with inherited retinal degenerative diseases who have limited treatment options. The report provides OCU-400’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the OCU-400 Market Report

The report provides insights into:

• A comprehensive product overview including the OCU-400 MoA, description, dosage and administration, research and development activities in potential indication like Retinitis pigmentosa and Leber congenital amaurosis.
• Elaborated details on OCU-400 regulatory milestones and other development activities have been provided in OCU-400 market report.
• The report also highlights OCU-400‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The OCU-400 market report also covers the patents information, generic entry and impact on cost cut.
• The OCU-400 market report contains current and forecasted OCU-400 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The OCU-400 market report also features the SWOT analysis with analyst views for OCU-400 in potential indications.

Methodology

The OCU-400 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OCU-400 Analytical Perspective by DelveInsight

• In-depth OCU-400 Market Assessment

This OCU-400 sales market forecast report provides a detailed market assessment of OCU-400 for potential indication like Retinitis pigmentosa and Leber congenital amaurosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted OCU-400 sales data uptil 2034.

• OCU-400 Clinical Assessment

The OCU-400 market report provides the clinical trials information of OCU-400 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

OCU-400 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

OCU-400 Market Potential & Revenue Forecast

• Projected market size for the OCU-400 and its key indications
• Estimated OCU-400 sales potential (OCU-400 peak sales forecasts)
• OCU-400 Pricing strategies and reimbursement landscape

OCU-400 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• OCU-400 Market positioning compared to existing treatments
• OCU-400 Strengths & weaknesses relative to competitors

OCU-400 Regulatory & Commercial Milestones

• OCU-400 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

OCU-400 Clinical Differentiation

• OCU-400 Efficacy & safety advantages over existing drugs
• OCU-400 Unique selling points

OCU-400 Market Report Highlights

• In the coming years, the OCU-400 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The OCU-400 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OCU-400’s dominance.
• Other emerging products for Retinitis pigmentosa and Leber congenital amaurosis are expected to give tough market competition to OCU-400 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OCU-400 in potential indications.
• Analyse OCU-400 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted OCU-400 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of OCU-400 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of OCU-400? How strong is OCU-400’s clinical and commercial performance?
• What is OCU-400’s clinical trial status in each individual indications such as Retinitis pigmentosa and Leber congenital amaurosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OCU-400 Manufacturers?
• What are the key designations that have been granted to OCU-400 for potential indications? How are they going to impact OCU-400’s penetration in various geographies?
• What is the current and forecasted OCU-400 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of OCU-400 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to OCU-400 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is OCU-400? What is the duration of therapy and what are the geographical variations in cost per patient?